在肝素诱导的血小板缺血症中,PF4抗原复合体的不稳定
Lubica Rauova1, Khalil Bdeir2, Ann H Rux3
1Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States.
Blood
|March 25, 2025
概括
全球肝素逆转剂 (UHRAs) 防止肝炎诱导的血小板缩 (HIT) 的有害免疫复合体. 这些药物使复合体不稳定,为HIT和相关条件提供了潜在的干预.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 生物化学 生物化学
背景情况:
- 氨酸诱导的血小板缺血 (HIT) 涉及针对血小板因子4 (PF4) 和未分离氨酸 (UFH) 复合物的抗体.
- 这些复合物是通过电静电相互作用形成的,这种相互作用是介质PF4和聚离子UFH之间的.
研究的目的:
- 为了研究合成的多化分子,全方位肝素逆转剂 (UHRAs),是否可以抑制HIT相关抗原复合物的形成和稳定性.
- 探索UHRAs作为对HIT的潜在治疗干预措施.
主要方法:
- 对UHRA进行了测试,以检测其抑制预制超大PF4-UFH复合体 (ULC) 的形成和解离的能力.
- 在HIT小鼠模型中评估UHRAs对抗体结合,血小板粘附和微血管血栓的作用.
主要成果:
- UHRA 抑制了现有的超大 PF4-UFH 复合物的形成和分离.
- UHRAs阻断了HIT抗体与PF4/氨酸和KKO抗体与血小板的结合.
- 在小鼠模型中,UHRAs降低了KKO诱导的血小板粘附和微血管血栓形成.
结论:
- UHRAs有效地抑制形成和破坏现有的免疫复合体的稳定,这些复合体是HIT病原体的核心.
- UHRAs代表了对HIT的潜在早期干预,可能提高抗凝剂的安全性.
- 像UHRAs这样的多化抑制剂也可能有利于其他涉及聚离子-PF4抗体复合物的疾病.
更多相关视频
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
583
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
583
Formation of the Platelet Plug
3.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.4K
Disorders of Hemostasis
671
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
671
Extrinsic and Intrinsic Pathways of Hemostasis
4.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
4.3K
Introduction to Hemostasis
4.6K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
4.6K
Clot Retraction and Fibrinolysis
3.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.0K


